Diagnostic implications of genetic copy number variation in epilepsy plus

Antonietta Coppola, Elena Cellini, Hannah Stamberger, Elmo Saarentaus, Valentina Cetica, Dennis Lal, Tania Djemie, Magdalena Bartnik-Glaska, Berten Ceulemans, J. Helen Cross, Tine Deconinck, Salvatore De Masi, Thomas Dorn, Renzo Guerrini, Dorotha Hoffman-Zacharska, Frank Kooy, Lieven Lagae, Nicholas Lench, Johannes R. Lemke, Ersilia LucenteforteFrancesca Madia, Heather C. Mefford, Deborah Morrogh, Peter Nuernberg, Aarno Palotie, An-Sofie Schoonjans, Pasquale Striano, Elzbieta Szczepanik, Anna Tostevin, Joris R. Vermeesch, Hilde Van Esch, Wim Van Paesschen, Jonathan J. Waters, Sarah Weckhuysen, Federico Zara, Peter De Jonghe, Sanjay M. Sisodiya, Carla Marini, EuroEPINOMICS RES Consortium, Rikke S. Moller, Helle Hjalgrim

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

19 Downloads (Pure)


Objective: Copy number variations (CNVs) represent a significant genetic risk for several neurodevelopmental disorders including epilepsy. As knowledge increases, reanalysis of existing data is essential. Reliable estimates of the contribution of CNVs to epilepsies from sizeable populations are not available. Methods: We assembled a cohort of 1255 patients with preexisting array comparative genomic hybridization or single nucleotide polymorphism array based CNV data. All patients had “epilepsy plus,” defined as epilepsy with comorbid features, including intellectual disability, psychiatric symptoms, and other neurological and nonneurological features. CNV classification was conducted using a systematic filtering workflow adapted to epilepsy. Results: Of 1097 patients remaining after genetic data quality control, 120 individuals (10.9%) carried at least one autosomal CNV classified as pathogenic; 19 individuals (1.7%) carried at least one autosomal CNV classified as possibly pathogenic. Eleven patients (1%) carried more than one (possibly) pathogenic CNV. We identified CNVs covering recently reported (HNRNPU) or emerging (RORB) epilepsy genes, and further delineated the phenotype associated with mutations of these genes. Additional novel epilepsy candidate genes emerge from our study. Comparing phenotypic features of pathogenic CNV carriers to those of noncarriers of pathogenic CNVs, we show that patients with nonneurological comorbidities, especially dysmorphism, were more likely to carry pathogenic CNVs (odds ratio = 4.09, confidence interval = 2.51-6.68; P = 2.34 × 10 −9). Meta-analysis including data from published control groups showed that the presence or absence of epilepsy did not affect the detected frequency of CNVs. Significance: The use of a specifically adapted workflow enabled identification of pathogenic autosomal CNVs in 10.9% of patients with epilepsy plus, which rose to 12.7% when we also considered possibly pathogenic CNVs. Our data indicate that epilepsy with comorbid features should be considered an indication for patients to be selected for a diagnostic algorithm including CNV detection. Collaborative large-scale CNV reanalysis leads to novel declaration of pathogenicity in unexplained cases and can promote discovery of promising candidate epilepsy genes.

Udgave nummer4
Sider (fra-til)689-706
Antal sider18
StatusUdgivet - 1. apr. 2019

Fingeraftryk Dyk ned i forskningsemnerne om 'Diagnostic implications of genetic copy number variation in epilepsy plus'. Sammen danner de et unikt fingeraftryk.